explore -WSS

explore

author：entertainment 2025-09-29 23:04:49 - browse：8

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Drug firms test therapies to halt Alzheimer’s before symptoms arise

leisure time

WSS

ReNAgade cuts staff seven months after raising $300 million

Neuroscience startup Neumora files for IPO

Feds fine Medicare Advantage plans for overcharging members

Neuroscience startup Neumora files for IPO

ReNAgade cuts staff seven months after raising $300 million

As pharma fights Medicare drug negotiation, hospitals, docs silent

explore

explore

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Despite FDA concern, risk that CAR

Psychedelics group wrestles with new pharma identity

Radiation, mainstay of cancer treatment, begins a fade

DIEP, the 'gold standard' of breast reconstruction, is under threat

Fetal surgery at risk from Dobbs and new abortion restrictions

Medical records are filled with copy

Flagship Pioneering launches a new biotech in two countries

The cancer drug shortage isn’t new — and neither are the solutions

Diversity in medical illustrations gets boost from Chidiebere Ibe

hotspot

How to make Best Hospitals ratings actually useful for patients

Takeda, Janssen join wearable maker to measure scratching

Disappointing trial forces Pfizer to pivot on obesity medicine plans

NYU Langone launches private ChatGPT for its health care data

U.K. Biobank has 500,000 peoples' genome sequences available

Australia’s approach to dialysis celebrates life

knowledge

entertainment

leisure time

focus